Spain Oncology Drugs Market Analysis Report [2022-30] I Insights10

Spain Oncology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Spain oncology drugs market will reach a value of $8.5 Bn from $3.8 Bn in 2022, growing at a CAGR of 10.6% during 2022-2030. The oncology drug market in Spain is dominated by a few large pharmaceutical companies such as Highlight Therapeutics, Peptomyc, and Oryzon Genomics. The oncology market in Spain is segmented by different therapeutic areas, into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. The market is also segmented based on treatment type, such as surgery, radiation therapy, chemotherapy, and targeted therapy.

ID: IN10ESPH018 CATEGORY: Pharmaceuticals GEOGRAPHY: Spain AUTHOR: Dr. Vishwa Modhia

Buy Now

Spain Oncology Drugs Market Analysis Summary

By 2030, it is anticipated that the Spain oncology drugs market will reach a value of $8.5 Bn from $3.8 Bn in 2022, growing at a CAGR of 10.6% during 2022-2030. The oncology drug market in Spain is a significant market within the European Union. Spain has a high incidence of cancer and a strong healthcare system, which drives demand for oncology drugs.

In 2020, the incident number of cancer cases in Spain was 282,421. The cumulative risk of cancer was 47%, of which the maximum risk is for prostate cancer i.e., 16.2%. In 2020, the number of deaths by cancer in Spain was 186 per 100,000 patients. Healthcare spending in Spain was about $2,724 per capita in 2020, which was 10.7% of their GDP. Every third woman and every second man in Spain is a cancer patient. But along with that, in the past 20 years, there has been a 20% increase in the nation's cancer survival rate. Precision in diagnosis and cutting-edge medical techniques enable this.

spain oncology drugs market analysis

Market Dynamics

Market Growth Drivers Analysis

Due to the most recent developments in oncological therapy, about 60% of foreign patients choose Spain for cancer treatment, and roughly 70% of paediatric cancer patients receive successful treatment in Spanish hospitals. In Spain, the prevalence of cancer patients is also increasing. Every third woman and every second man in Spain is a cancer patient. The country’s cancer survival rate has increased by 20% in the past 20 years. This is made possible by accurate diagnosis and advanced treatment methods.

Competitive Landscape

Key Players

Oryzon Genomics (ESP)
Ona Therapeutics (ESP)
Peptomyc (ESP)
Highlight Therapeutics (ESP)
Aspen Europe
Hoffmann-La Roche Ltd
Novartis AG
Gilead Sciences Inc
Bayer AG

Notable Recent Deals

July 2022: Oryzon Genomics, a clinical-stage biopharmaceutical company leveraging oncological epigenetics to develop therapies in diseases with strong unmet medical needs, announced the start of a preclinical collaboration with the CMT Research Foundation (CMTRF), a U.S.-based patient-led, non-profit organization focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease, to explore Oryzon’s histone deacetylase 6 (HDAC6) inhibitors.

January 2020: Spain's Esteve sells a plant and then buys one as it refocuses on oncology drugs. Esteve, which is turning its focus toward branded and specialty drugs, has a deal to buy Berlin-based Riemser from private investment group Ardian. In the deal, Esteve gets a German manufacturing site and a portfolio of specialty drugs targeted at hospitals. Riemser primarily makes and sells oncology and neurology drugs as well as what it calls “niche therapies.”

Regulations and Reimbursement

Spain's citizens have access to cancer treatments through its national healthcare system. The nation's drug approval and regulation are handled by the Spanish Agency of Medicines and Medical Devices (AEMPS). The Spanish Public Health System (SNS)'s Pricing and Reimbursement (PR) is then established by the Inter-Ministerial Commission for the Pricing of Medicines (CIPM).

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Drugs Market Segmentation

By Drug class

Cytotoxic drugs
- Alkylating agents
- Antimetabolites
- Others
Targeted drugs
- Monoclonal antibodies
- Others
Hormonal drugs
Others

By Therapy

Chemotherapy
Targeted therapy
Immunotherapy

By Indication

Lung cancer
Stomach cancer
Colorectal cancer
Breast cancer
Prostate cancer
Others

By Dosage form

Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled syringes
- Others

By Distribution channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.